profit from every $100 of sales.
$0$100
Perspective Therapeutics
$0.94+11.95% today
-54.4% in 1 year
1-year low $0.791-year high $5.65
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Perspective Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $10.8 million in 2022 to $0 in 2025, with -$103 million of profit last year.
SalesProfit
Perspective Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Perspective Therapeutics | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Perspective Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 11 | 0 | 0 | 0 | |
| 5 | – | – | – | |
| -7 | -41 | -67 | -114 | |
| -7 | -39 | -78 | -101 | |
| -7 | -47 | -79 | -103 | |
| -0.50 | -1.74 | -1.23 | -1.40 | |
| 42.8% | – | – | – | |
| -68.5% | – | – | – | |
| -67.4% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 64 | 98 | 341 | 267 |
| Cash | 56 | 9 | 62 | 31 |
| Total debt | 1 | 3 | 4 | 3 |
| Total liabilities | 3 | 23 | 50 | 60 |
| 61 | 75 | 291 | 207 | |
| 14 | 27 | 64 | 74 | |
| -9.4% | -40.7% | -21.5% | -39.1% | |
| -11.9% | -61.9% | -27.3% | -49.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -37 | -18 | -82 | |
| 0 | 1 | 54 | 13 | |
| -8 | -38 | -73 | -95 | |
| Dividends paid | 0 | – | – | – |
| – | – | – | – | |
| 1 | 4 | 5 | 9 |
Valuation
- –
- –
- –
- 1.1×
- 10.6×
- –
- –
- -7.0%
- -6.4%
- 0.0%
Profitability
- 42.8%
- -68.5%
- -67.4%
- -14,926.9%
- -23.4%
- -34.8%
- -41.8%
- -27.1%
- -23.6%
- 16,016.4%
Growth
- –
- –
- −31.0%
- –
- +7.7%
Financial health
- -7.8×
- 0.01
- 0.6%
- -5,976.0×
- 8.75
- 8.75
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 15%of 963
Bottom 5%of 894
Bottom 12%of 991
What analysts expect
- Average price target
- $11.75
- Range
- $7.00 – $16.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.25 | -0.29 | +13.8% |
| Mar 16, 2026 | -0.51 | -0.37 | −37.8% |
| Nov 10, 2025 | -0.35 | -0.33 | −6.1% |
| Aug 13, 2025 | -0.30 | -0.30 | +0.0% |
| May 12, 2025 | -0.25 | -0.28 | +10.7% |
| Mar 26, 2025 | -0.25 | -0.26 | +3.8% |
| Nov 12, 2024 | -0.21 | -0.21 | +0.0% |
| Aug 12, 2024 | -0.17 | -0.21 | +19.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
65Pass
Philip Fisher
40No pass
Peter Lynch
50No pass
Joel Greenblatt
0No pass
Charlie Munger
34No pass
Terry Smith
33No pass
Questions about Perspective Therapeutics
Is Perspective Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Perspective Therapeutics AI analysis
What does Perspective Therapeutics do?
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. It is in Medical - Devices.
Does Perspective Therapeutics pay a dividend?
No. Perspective Therapeutics does not pay a dividend at the moment.
Is Perspective Therapeutics stock halal?
Questionable. Perspective Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Perspective Therapeutics stock done over the past year?
Down 54.4% over the past twelve months, to $0.94. It traded between $0.79 and $5.65 and is 83.3% below its high.
Who are Perspective Therapeutics's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Perspective Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.